{"id":363238,"date":"2025-09-15T07:45:00","date_gmt":"2025-09-14T23:45:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=363238"},"modified":"2025-09-15T07:45:00","modified_gmt":"2025-09-14T23:45:00","slug":"%e8%80%90%e8%b3%a6%e5%ba%b77%e9%a0%85%e6%9c%80%e6%96%b0%e7%9c%9f%e5%af%a6%e4%b8%96%e7%95%8c%e6%95%b8%e6%93%9a%e5%b0%87%e4%ba%ae%e7%9b%b8%e7%ac%ac18%e5%b1%86iga%e8%85%8e%e7%97%85%e5%9c%8b","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=363238","title":{"rendered":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002<\/li>\n<li>\u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002<\/li>\n<li>\u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002<\/li>\n<li>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">\u4e0a\u6d77<\/span><span class=\"legendSpanClass\">2025\u5e749\u670815\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON<sup>\u00ae<\/sup>\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002<\/p>\n<p>\u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002<\/p>\n<p>\u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002<\/p>\n<p>\u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002<\/p>\n<p>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002<\/p>\n<p><b>\u6578\u64da\u6458\u8981<\/b><\/p>\n<p><b>01 \u7de8\u865f\uff1aP-45<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Beyond Nine Months: Real &#8211; World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027<br \/><b>\u5167\u5bb9\u6982\u8ff0\uff1a<\/b>\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662<br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662<\/p>\n<p><b>02 \u7de8\u865f\uff1aP-44<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Efficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76<br \/><b>\u5167\u5bb9\u6982\u8ff0<\/b>\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662<\/p>\n<p><b>03 \u7de8\u865f\uff1aP-43<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Budesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a<br \/><b>\u5167\u5bb9\u6982\u8ff0<\/b>\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662<\/p>\n<p><b>04 \u7de8\u865f\uff1aP-63<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>First real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u9996\u500b\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da<br \/><b>\u5167\u5bb9\u6982\u8ff0<\/b>\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662<\/p>\n<p><b>05 \u7de8\u865f\uff1aP-64<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Efficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76<br \/><b>\u5167\u5bb9\u6982\u8ff0\uff1a<\/b>\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662<\/p>\n<p><b>06 \u7de8\u865f\uff1aP-48<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Nefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76<br \/><b>\u5167\u5bb9\u6982\u8ff0\uff1a<\/b>\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662<\/p>\n<p><b>07 \u7de8\u865f\uff1aP-62<br \/><\/b><b>\u82f1\u6587\u6a19\u984c\uff1a<\/b>Early Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function<br \/><b>\u4e2d\u6587\u6a19\u984c\uff1a<\/b>\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a<br \/><b>\u5167\u5bb9\u6982\u8ff0\uff1a<\/b>\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002<br \/><b>\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a<\/b>\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662<\/p>\n<p><b>\u95dc\u65bc\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\uff08NEFECON<sup>\u00ae<\/sup>\uff09<\/b><\/p>\n<p>\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>(NEFECON<sup>\u00ae<\/sup>)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d<sup><span id=\"spanHghltbacc\">[1]<\/span><\/sup>\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%<sup><span id=\"spanHghltf64b\">[2]<\/span><\/sup>\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74<sup><span id=\"spanHghlt5633\">[3]<\/span><\/sup>\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%<sup><span id=\"spanHghlt6448\">[4]<\/span><\/sup>\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002<\/p>\n<p>2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7<sup>\u00ae<\/sup>\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002<\/p>\n<p><b>\u95dc\u65bc\u96f2\u9802\u65b0\u8000<\/b><\/p>\n<p>\u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a <a href=\"https:\/\/www.everestmedicines.com\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color: #0000FF\">www.everestmedicines.com<\/a>\u3002\u00a0<\/p>\n<p><b>\u524d\u77bb\u6027\u8072\u660e<\/b><\/p>\n<p>\u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002<\/p>\n<p><b><span>\u53c2\u8003\u6587\u732e<\/span><\/b><\/p>\n<p><span>[1] Lafayette R,et al. Lancet. 2023 <span class=\"xn-chron\">Sep 9<\/span>;402(10405):859-870.<\/span><\/p>\n<p><span>[2] 2023ASN. Oral presentation.<\/span><\/p>\n<p><span>[3] Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.<\/span><\/p>\n<p><span>[4] Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24.<\/span><\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5&#8230;<\/p>\n","protected":false},"author":16,"featured_media":199219,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-363238","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002  \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002  \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002  \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002  \u4e0a\u6d772025\u5e749\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e  Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.  2023ASN. Oral presentation.  Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.  Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=363238\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002  \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002  \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002  \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002  \u4e0a\u6d772025\u5e749\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e  Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.  2023ASN. Oral presentation.  Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.  Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=363238\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-14T23:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\",\"datePublished\":\"2025-09-14T23:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238\"},\"wordCount\":223,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238\",\"name\":\"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"datePublished\":\"2025-09-14T23:45:00+00:00\",\"description\":\"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002 \u4e0a\u6d772025\u5e749\u670815\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\\\/min\\\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870. 2023ASN. Oral presentation. Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886. Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":\"3000\",\"height\":\"1990\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=363238#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002  \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002  \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002  \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002  \u4e0a\u6d772025\u5e749\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e  Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.  2023ASN. Oral presentation.  Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.  Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=363238","og_locale":"zh_TW","og_type":"article","og_title":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002  \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002  \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002  \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002  \u4e0a\u6d772025\u5e749\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e  Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.  2023ASN. Oral presentation.  Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.  Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0","og_url":"https:\/\/pingtungtimes.com.tw\/?p=363238","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2025-09-14T23:45:00+00:00","og_image":[{"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"","width":"","height":""}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_image":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703","datePublished":"2025-09-14T23:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238"},"wordCount":223,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=363238","url":"https:\/\/pingtungtimes.com.tw\/?p=363238","name":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","datePublished":"2025-09-14T23:45:00+00:00","description":"\u8010\u8ce6\u5eb7\u00ae\u5c07\u5728\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN 2025\uff09\u4e0a\uff0c\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u5f97\u570b\u5167\u5916\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\uff0c\u8b49\u5be6\u4e86\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u57fa\u77f3\u6cbb\u7642\u7684\u9818\u5c0e\u5730\u4f4d\u3002 \u4e0a\u6d772025\u5e749\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- 2025\u5e74\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703\uff08IIgANN\uff09\u5c07\u65bc9\u670817\u65e5\u81f320\u65e5\u5728\u6377\u514b\u5171\u548c\u570b\u5e03\u62c9\u683c\u8209\u884c\u3002\u8010\u8ce6\u5eb7\u00ae\uff08\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0cNEFECON\u00ae\uff09\u5728\u6b64\u76db\u6703\u4e2d\u5c07\u5c55\u793a7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\uff0c\u9032\u4e00\u6b65\u5c55\u73fe\u5176\u5728\u76f8\u95dc\u9818\u57df\u7684\u6df1\u5165\u7814\u7a76\u9032\u5c55\u3002 \u6b64\u6b21\u516c\u5e03\u7684\u6700\u65b0\u6578\u64da\u4f86\u81ea\u4e2d\u570b\u591a\u5bb6\u9802\u5c16\u91ab\u9662\u7684\u81e8\u5e8a\u5be6\u8e10\uff0c\u5f9e\u591a\u500b\u7dad\u5ea6\u6df1\u5165\u63a2\u8a0e\u4e86\u8010\u8ce6\u5eb7\u00ae\u5728IgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u4e09\u500b\u65b9\u9762\u5747\u5c55\u73fe\u51fa\u986f\u8457\u7684\u81e8\u5e8a\u50f9\u503c\uff1a\u5728\u771f\u5be6\u4e16\u754c\u7528\u85e5\u4e2d\uff0c\u5176\u5c0d\u56e0\u6cbb\u7642\u7684\u50f9\u503c\u5f97\u5230\u9a57\u8b49\uff1b\u65e9\u671f\u5e72\u9810\u88ab\u8b49\u5be6\u5c0d\u6e1b\u5c11\u86cb\u767d\u5c3f\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u65b9\u9762\u5177\u6709\u91cd\u8981\u610f\u7fa9\uff1b\u540c\u6642\uff0c\u8d85\u904e9\u500b\u6708\u7684\u5ef6\u9577\u6cbb\u7642\u6578\u64da\u4e5f\u63d0\u4f9b\u4e86\u9577\u671f\u7642\u6548\u8207\u5b89\u5168\u6027\u7684\u6709\u529b\u8b49\u64da\u3002 \u9019\u4e9b\u771f\u5be6\u4e16\u754c\u8b49\u64da\u4e0d\u50c5\u5f4c\u88dc\u4e86\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff08RCT\uff09\u5728\u81e8\u5e8a\u61c9\u7528\u5834\u666f\u4e2d\u7684\u5c40\u9650\u6027\uff0c\u4e5f\u9032\u4e00\u6b65\u5145\u5be6\u4e86\u300c\u5c0d\u56e0\u6cbb\u7642\u3001\u5118\u65e9\u6cbb\u7642\u3001\u9577\u671f\u6cbb\u7642\u300d\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u5f37\u5316\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70ba\u5168\u7403\u9996\u500b\u91dd\u5c0dIgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u7684\u81e8\u5e8a\u5730\u4f4d\u8207\u5b78\u8853\u5f71\u97ff\u529b\uff0c\u70ba\u63a8\u52d5IgA\u814e\u75c5\u7684\u8a3a\u7642\u6a21\u5f0f\u8b8a\u9769\u548c\u5168\u7403\u7814\u7a76\u9032\u5c55\u63d0\u4f9b\u4e86\u91cd\u8981\u79d1\u5b78\u4f9d\u64da\u3002 \u6191\u501f\u5275\u65b0\u7684\u4f5c\u7528\u6a5f\u5236\u548c\u7a81\u51fa\u7684\u81e8\u5e8a\u512a\u52e2\uff0c\u8010\u8ce6\u5eb7\u00ae\u5148\u5f8c\u88ab\u7d0d\u5165\u300a2024\u7248KDIGO IgA\u814e\u75c5\u548cIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u7ba1\u7406\u5be6\u8e10\u6307\u5357\uff08\u516c\u958b\u5be9\u67e5\u7248\uff09\u300b\u4ee5\u53ca\u300a\u4e2d\u570b\u6210\u4ebaIgA\u814e\u75c5\u53caIgA\u8840\u7ba1\u708e\u81e8\u5e8a\u5be6\u8e10\u6307\u5357\uff08\u9810\u5be9\u7248\u672c\uff09\u300b\uff0c\u6210\u70ba\u76ee\u524d\u552f\u4e00\u540c\u6642\u7372\u570b\u969b\u8207\u570b\u5167\u6307\u5357\u63a8\u85a6\u7684IgA\u814e\u75c5\u5c0d\u56e0\u6cbb\u7642\u85e5\u7269\u3002\u9019\u4e0d\u50c5\u6539\u8b8a\u4e86\u50b3\u7d71\u7684IgA\u814e\u75c5\u6cbb\u7642\u65b9\u6848\uff0c\u5f37\u8abf\u5c0d\u56e0\u6cbb\u7642\u548c\u652f\u6301\u6cbb\u7642\u9700\u540c\u6642\u9032\u884c\uff0c\u4e5f\u78ba\u7acb\u4e86\u8010\u8ce6\u5eb7\u00ae\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u7684\u57fa\u77f3\u5730\u4f4d\u3002\u8010\u8ce6\u5eb7\u00ae\u65bc2024\u5e7411\u6708\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c2025\u5e748\u6708\u5176\u64f4\u7522\u88dc\u5145\u7533\u8acb\u6b63\u5f0f\u7372\u5f97\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u3002 \u8010\u8ce6\u5eb7\u00ae\u662f\u76ee\u524d\u5168\u7403\u9996\u500b\u540c\u6642\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u3001\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u82f1\u570b\u85e5\u54c1\u548c\u5065\u5eb7\u7522\u54c1\u7ba1\u7406\u5c40\uff08MHRA\uff09\u53ca\u96f2\u9802\u65b0\u8000\u5176\u4ed6\u4e9e\u6d32\u6388\u6b0a\u5340\u57df\uff08\u4e2d\u570b\u9999\u6e2f\u3001\u4e2d\u570b\u6fb3\u9580\u3001\u4e2d\u570b\u53f0\u7063\u3001\u65b0\u52a0\u5761\u53ca\u97d3\u570b\uff09\u5b8c\u5168\u6279\u51c6\u7684IgA\u814e\u75c5\u6cbb\u7642\u85e5\u7269\u3002 \u6578\u64da\u6458\u8981 01 \u7de8\u865f\uff1aP-45\u82f1\u6587\u6a19\u984c\uff1aBeyond Nine Months: Real - World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy\u4e2d\u6587\u6a19\u984c\uff1a\u8d85\u8d8a\u4e5d\u6708\u4e4b\u9650\uff1a\u5ef6\u9577\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5728IgA\u814e\u75c5\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u5c0dIgA\u814e\u75c5\u60a3\u8005\u9032\u884c12\u500b\u6708\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff0c\u4e26\u8207\u50b3\u7d71\u6cbb\u7642\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\u986f\u793a\uff0c12\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u4e14\u8207\u50b3\u7d71\u7684\u5168\u8eab\u7cd6\u76ae\u8cea\u6fc0\u7d20\u53ca\u514d\u75ab\u6291\u5236\u5291\u6cbb\u7642\u76f8\u6bd4\uff0c\u5177\u6709\u66f4\u597d\u7684\u5b89\u5168\u6027\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u694a\u79c0\uff0c\u897f\u6e56\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u676d\u5dde\u5e02\u7b2c\u4e00\u4eba\u6c11\u91ab\u9662\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u6b50\u967d\u6893\u83ef\uff0c\u6fb3\u9580\u93e1\u6e56\u91ab\u9662 02 \u7de8\u865f\uff1aP-44\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642IgA\u814e\u75c5\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u56de\u9867\u6027\u968a\u5217\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u53ef\u986f\u8457\u964d\u4f4eIgA\u814e\u75c5\u60a3\u8005\u7684\u86cb\u767d\u5c3f\u6c34\u5e73\u4e26\u6539\u5584\u814e\u529f\u80fd\uff0c\u4e14\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u9019\u4e9b\u7d50\u679c\u652f\u6301\u5176\u4f5c\u70baIgA\u814e\u75c5\u4e00\u7dda\u6cbb\u7642\u9078\u64c7\u7684\u6f5b\u529b\u3002\u4ecd\u9700\u958b\u5c55\u66f4\u5927\u6a23\u672c\u91cf\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\u4ee5\u9032\u4e00\u6b65\u9a57\u8b49\u9019\u4e9b\u7d50\u679c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 03 \u7de8\u865f\uff1aP-43\u82f1\u6587\u6a19\u984c\uff1aBudesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u7528\u65bc\u5408\u4e26\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u7684IgA\u814e\u75c5\uff1a\u5169\u4f8b\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u540c\u6642\u60a3\u6709IgA\u814e\u75c5\u548c\u6162\u6027\u4e59\u578b\u809d\u708e(HBV)\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u806f\u5408\u5f37\u5316\u652f\u6301\u6cbb\u7642\u53ef\u6709\u6548\u6539\u5584\u4f34\u6709HBV\u5408\u4e26\u611f\u67d3\u7684IgA\u814e\u75c5\u60a3\u8005\u7684\u814e\u81df\u7d50\u5c40\uff0c\u4e14\u672a\u5f15\u767c\u75c5\u6bd2\u518d\u6fc0\u6d3b\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u9019\u4e00\u7279\u6b8a\u4eba\u7fa4\u4e2d\u7684\u4f7f\u7528\u63d0\u4f9b\u4e86\u5faa\u8b49\u4f9d\u64da\uff0c\u63d0\u793a\u5728\u56b4\u683c\u76e3\u6e2cHBV\u751f\u7269\u6a19\u8a8c\u7269\u7684\u524d\u63d0\u4e0b\uff0c\u901a\u904e\u9776\u5411\u8178\u9053\u514d\u75ab\u8abf\u7bc0\u56de\u8178\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\u4e2d\u9ecf\u819cB\u7d30\u80de\u7684\u6578\u91cf\u548c\u6d3b\u6027\uff0c\u53ef\u80fd\u662f\u4e00\u7a2e\u512a\u9078\u7b56\u7565\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u9673\u838e\u838e\u3001\u674e\u8cb4\u68ee\uff0c\u56db\u5ddd\u7701\u91ab\u5b78\u79d1\u5b78\u9662\u2022\u56db\u5ddd\u7701\u4eba\u6c11\u91ab\u9662 04 \u7de8\u865f\uff1aP-63\u82f1\u6587\u6a19\u984c\uff1aFirst real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis\u4e2d\u6587\u6a19\u984c\uff1a\u9996\u500b\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u7684\u771f\u5be6\u4e16\u754c\u8b49\u64da\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5c0d\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\u7684\u7642\u6548\u3002\u7d50\u679c\u986f\u793a\uff0c\u5728\u771f\u5be6\u4e16\u754c\u74b0\u5883\u4e2d\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u5152\u7ae5IgA\u814e\u75c5\u6216IgA\u8840\u7ba1\u708e\u814e\u708e\uff08IgAVN\uff09\u60a3\u8005\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u548c\u8840\u5c3f\u3002\u7136\u800c\uff0c\u5176\u5c0d\u4e0b\u4e18\u8166-\u5782\u9ad4-\u814e\u4e0a\u817a\u8ef8\u7684\u6f5b\u5728\u6291\u5236\u4ecd\u9700\u5f15\u8d77\u5152\u7ae5\u814e\u81df\u79d1\u91ab\u751f\u7684\u9ad8\u5ea6\u95dc\u6ce8\u8207\u8b39\u614e\u8a55\u4f30\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u745c\u3001\u5468\u5efa\u83ef\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u540c\u6fdf\u91ab\u9662 05 \u7de8\u865f\uff1aP-64\u82f1\u6587\u6a19\u984c\uff1aEfficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u764226\u4f8b\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u7279\u5fb5\uff1a\u4e00\u9805\u771f\u5be6\u4e16\u754c\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u771f\u5be6\u4e16\u754c\u81e8\u5e8a\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\u9019\u9805\u771f\u5be6\u4e16\u754c\u5206\u6790\u986f\u793a\uff0c\u8010\u8ce6\u5eb7\u00ae\u5728\u4e2d\u570bIgA\u814e\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u6301\u7e8c\u7684\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\uff0c\u5c24\u5176\u662f\u814e\u529f\u80fd\u5c1a\u53ef\uff08eGFR \u226535 mL\/min\/1.73m\u00b2\uff09\u7684\u60a3\u8005\uff0c\u8868\u73fe\u70ba\u86cb\u767d\u5c3f\u9010\u6b65\u4e0b\u964d\u548c\u8840\u5c3f\u6d88\u9000\u3002\u826f\u597d\u7684\u5b89\u5168\u6027\u9032\u4e00\u6b65\u652f\u6301\u5176\u5728\u8a72\u4eba\u7fa4\u4e2d\u7684\u81e8\u5e8a\u61c9\u7528\u50f9\u503c\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u5f35\u8ecd\u8ecd\u3001\u8d99\u5360\u6b63\uff0c\u912d\u5dde\u5927\u5b78\u7b2c\u4e00\u9644\u5c6c\u91ab\u9662 06 \u7de8\u865f\uff1aP-48\u82f1\u6587\u6a19\u984c\uff1aNefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study\u4e2d\u6587\u6a19\u984c\uff1a\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684\u539f\u767c\u6027IgA\u814e\u75c5\u60a3\u8005\uff1a\u4e00\u9805\u70ba\u671f6\u500b\u6708\u7684\u89c0\u5bdf\u6027\u7814\u7a76\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u8010\u8ce6\u5eb7\u00ae\u5728\u5408\u4e26\u814e\u529f\u80fd\u4e0d\u5168\u7684IgA\u814e\u75c5\u60a3\u8005\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u7d93\u904e6\u500b\u6708\u7684\u8010\u8ce6\u5eb7\u00ae\u6cbb\u7642\u986f\u793a\uff0c\u5728\u9ad8\u98a8\u96aaIgA\u814e\u75c5\u4eba\u7fa4\u4e2d\u53ef\u6f5b\u5728\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u540c\u6642\u4f34\u6709\u9069\u5ea6\u7684\u86cb\u767d\u5c3f\u4e0b\u964d\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u65b9\u660e\uff0c\u5927\u9023\u91ab\u79d1\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 07 \u7de8\u865f\uff1aP-62\u82f1\u6587\u6a19\u984c\uff1aEarly Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function\u4e2d\u6587\u6a19\u984c\uff1a\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u65e9\u671f\u5e72\u9810IgA\u814e\u75c5\uff1a\u5169\u4f8b\u986f\u793a\u86cb\u767d\u5c3f\u6e1b\u5c11\u548c\u7a69\u5b9a\u814e\u529f\u80fd\u7684\u75c5\u4f8b\u5831\u544a\u5167\u5bb9\u6982\u8ff0\uff1a\u65e8\u5728\u8a55\u4f30\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u7d50\u679c\u986f\u793a\uff0c\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\u5728\u814e\u529f\u80fd\u6b63\u5e38\u7684\u65e9\u671fIgA\u814e\u75c5\u6cbb\u7642\u4e2d\u53ef\u986f\u8457\u964d\u4f4e\u86cb\u767d\u5c3f\u3001\u7a69\u5b9a\u814e\u529f\u80fd\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002\u5c0d\u65bcIgA\u814e\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u65e9\u671f\u8a3a\u65b7\u548c\u5e72\u9810\u5c24\u70ba\u91cd\u8981\u3002\u4e3b\u8981\u4f5c\u8005\u53ca\u91ab\u9662\uff1a\u8096\u66c9\u71d5\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u65bc\u8010\u8ce6\u5eb7\u00ae\uff08NEFECON\u00ae\uff09 \u8010\u8ce6\u5eb7\u00ae(NEFECON\u00ae)\u662f\u5e03\u5730\u5948\u5fb7\u8178\u6eb6\u81a0\u56ca\uff0c\u4f5c\u70ba\u5168\u7403\u9996\u500b\u5c0d\u56e0\u6cbb\u7642IgA\u814e\u75c5\u7684\u85e5\u7269\uff0c\u662f\u9776\u5411\u8178\u9053\u9ecf\u819cB\u7d30\u80de\u7684\u514d\u75ab\u8abf\u7bc0\u5291\uff0c\u80fd\u6e1b\u5c1150%\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u5728\u4e2d\u570b\u4eba\u7fa4\u4e2d\u80fd\u5ef6\u7de9\u814e\u529f\u80fd\u8870\u9000\u905466%\uff0c\u9810\u8a08\u5c07\u75be\u75c5\u9032\u5c55\u81f3\u900f\u6790\u6216\u814e\u79fb\u690d\u7684\u6642\u9593\u5ef6\u7de912.8\u5e74\u3002\u540c\u6642\u5e03\u5730\u5948\u5fb7\u9996\u904e\u4ee3\u8b1d\u7387\u905490%\uff0c\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u8010\u8ce6\u5eb7\u00ae\u5c08\u70baIgA\u814e\u75c5\u60a3\u8005\u7814\u5236\uff0c\u6bcf\u9846\u81a0\u56ca\u542b\u5e03\u5730\u5948\u5fb74mg\uff0c\u901a\u904e\u7279\u6b8a\u7684\u9072\u91cb\u53ca\u7de9\u91cb\u96d9\u91cd\u5236\u5291\u5de5\u85dd\uff0c\u5c07\u5e03\u5730\u5948\u5fb7\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u9776\u5411\u91cb\u653e\u65bc\u56de\u8178\u672b\u7aef\u7684\u9ecf\u819cB\u7d30\u80de\uff08\u5305\u62ec\u6d3e\u723e\u96c6\u5408\u6dcb\u5df4\u7d50\uff09\uff0c\u4e09\u5c64\u5305\u8863\u5fae\u4e38\u6301\u7e8c\u7a69\u5b9a\u91cb\u653e\u5e03\u5730\u5948\u5fb7\uff0c\u9ad8\u6fc3\u5ea6\u8986\u84cb\u6574\u500b\u9776\u5340\u57df\uff0c\u5f9e\u800c\u6e1b\u5c11\u8a98\u767cIgA\u814e\u75c5\u7684\u534a\u4e73\u7cd6\u7f3a\u9677\u7684IgA1\uff08Gd-IgA1\uff09\u7522\u751f\uff0c\u9032\u800c\u5e72\u9810\u767c\u75c5\u6a5f\u5236\u4e0a\u6e38\u968e\u6bb5\uff0c\u9054\u5230\u6cbb\u7642IgA\u814e\u75c5\u7684\u4f5c\u7528\u3002 2019\u5e746\u6708\uff0c\u96f2\u9802\u65b0\u8000\u8207Calliditas Therapeutics \u7c3d\u8a02\u7368\u5bb6\u6388\u6b0a\u8a31\u53ef\u5354\u8b70\uff0c\u7372\u5f97\u5728\u5927\u4e2d\u83ef\u5730\u5340\u548c\u65b0\u52a0\u5761\u958b\u767c\u4ee5\u53ca\u5546\u696d\u5316\u8010\u8ce6\u5eb7\u00ae\u7684\u6b0a\u5229\u3002\u8a72\u5354\u8b70\u65bc2022\u5e743\u6708\u64f4\u5c55\uff0c\u5c07\u97d3\u570b\u7d0d\u5165\u96f2\u9802\u65b0\u8000\u7684\u6388\u6b0a\u8a31\u53ef\u7bc4\u570d\u3002 \u95dc\u65bc\u96f2\u9802\u65b0\u8000 \u96f2\u9802\u65b0\u8000\u662f\u4e00\u5bb6\u5c08\u6ce8\u65bc\u5275\u65b0\u85e5\u548c\u75ab\u82d7\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u88fd\u9020\u548c\u5546\u696d\u5316\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u6eff\u8db3\u4e9e\u6d32\u5e02\u5834\u5c1a\u672a\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u96f2\u9802\u65b0\u8000\u7684\u7ba1\u7406\u5718\u968a\u5728\u4e2d\u570b\u53ca\u5168\u7403\u9818\u5148\u88fd\u85e5\u4f01\u696d\u5f9e\u4e8b\u904e\u9ad8\u8cea\u91cf\u7814\u767c\u3001\u81e8\u5e8a\u958b\u767c\u3001\u85e5\u653f\u4e8b\u52d9\u3001\u5316\u5b78\u88fd\u9020\u8207\u63a7\u5236\uff08CMC\uff09\u3001\u696d\u52d9\u767c\u5c55\u548c\u5546\u696d\u5316\u904b\u71df\uff0c\u64c1\u6709\u6df1\u539a\u7684\u5c08\u9577\u548c\u8c50\u5bcc\u7684\u7d93\u9a57\u3002\u96f2\u9802\u65b0\u8000\u5df2\u6253\u9020\u591a\u6b3e\u75be\u75c5\u9996\u5275\u6216\u8005\u540c\u985e\u6700\u4f73\u7684\u85e5\u7269\u7d44\u5408\uff0c\u516c\u53f8\u7684\u6cbb\u7642\u9818\u57df\u5305\u62ec\u814e\u79d1\u75be\u75c5\u3001\u611f\u67d3\u6027\u548c\u50b3\u67d3\u6027\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u6709\u95dc\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u516c\u53f8\u7db2\u7ad9\uff1a www.everestmedicines.com\u3002\u00a0 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u6240\u767c\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u6703\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\uff0c\u4e43\u57fa\u65bc\u672c\u516c\u53f8\u6216\u7ba1\u7406\u5c64\u5728\u505a\u51fa\u8868\u8ff0\u6642\u5c0d\u516c\u53f8\u696d\u52d9\u904b\u71df\u60c5\u6cc1\u53ca\u8ca1\u52d9\u72c0\u6cc1\u7684\u73fe\u6709\u770b\u6cd5\u3001\u76f8\u4fe1\u3001\u548c\u73fe\u6709\u9810\u671f\uff0c\u53ef\u80fd\u6703\u4f7f\u7528\u300c\u5c07\u300d\u3001\u300c\u9810\u671f\u300d\u3001\u300c\u9810\u6e2c\u300d\u3001\u300c\u671f\u671b\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u8a08\u5283\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u9810\u4f30\u300d\u3001\u300c\u78ba\u4fe1\u300d\u53ca\u5176\u4ed6\u985e\u4f3c\u8a5e\u8a9e\u9032\u884c\u8868\u8ff0\u3002\u9019\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e26\u975e\u5c0d\u672a\u4f86\u696d\u7e3e\u7684\u4fdd\u8b49\uff0c\u6703\u53d7\u5230\u98a8\u96aa\u3001\u4e0d\u78ba\u5b9a\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u7bc4\u570d\uff0c\u96e3\u4ee5\u9810\u8a08\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u5011\u7684\u696d\u52d9\u3001\u7af6\u722d\u74b0\u5883\u3001\u653f\u6cbb\u3001\u7d93\u6fdf\u3001\u6cd5\u5f8b\u548c\u793e\u6703\u60c5\u6cc1\u7684\u672a\u4f86\u8b8a\u5316\u53ca\u767c\u5c55\u7b49\u5404\u7a2e\u56e0\u7d20\u53ca\u5047\u8a2d\u7684\u5f71\u97ff\uff0c\u5be6\u969b\u7d50\u679c\u53ef\u80fd\u6703\u8207\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8cc7\u6599\u6709\u8f03\u5927\u5dee\u5225\u3002\u672c\u516c\u53f8\u53ca\u5404\u9644\u5c6c\u516c\u53f8\u3001\u5404\u4f4d\u8463\u4e8b\u3001\u7ba1\u7406\u4eba\u54e1\u3001\u9867\u554f\u53ca\u4ee3\u7406\u672a\u66fe\u4e14\u6982\u4e0d\u627f\u64d4\u66f4\u65b0\u8a72\u7a3f\u4ef6\u6240\u8f09\u524d\u77bb\u6027\u8868\u8ff0\u4ee5\u53cd\u6620\u5728\u672c\u65b0\u805e\u7a3f\u767c\u5e03\u65e5\u5f8c\u6700\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u9805\u76ee\u6216\u60c5\u5f62\u7684\u4efb\u4f55\u7fa9\u52d9\uff0c\u9664\u975e\u6cd5\u5f8b\u8981\u6c42\u3002 \u53c2\u8003\u6587\u732e Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870. 2023ASN. Oral presentation. Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886. Edsb\u00e4cker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. \u00a0","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=363238"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":"3000","height":"1990"},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=363238#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u8010\u8ce6\u5eb7\u00ae7\u9805\u6700\u65b0\u771f\u5be6\u4e16\u754c\u6578\u64da\u5c07\u4eae\u76f8\u7b2c18\u5c46IgA\u814e\u75c5\u570b\u969b\u7814\u8a0e\u6703"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/363238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=363238"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/363238\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/199219"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=363238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=363238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=363238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}